Blincyto

Active Ingredient(s): Blinatumomab
FDA Approved: * December 3, 2014
Pharm Company: * AMGEN
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Blincyto Overview

Blinatumomab, sold under the brand name Blincyto, is a biopharmaceutical medication used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It belongs to a class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells. Blinatumomab specifically targets the CD19 antigen present on B cells.[2] In Decembe...

Read more Blincyto Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Blinatumomab

Recent Blincyto Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Blinatumomab
  • Injection: 35mcg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Blincyto: (1 result)

Sorted by National Drug Code
  • 55513-160 Blincyto Intravenous Kit by Amgen Inc

Other drugs which contain Blinatumomab or a similar ingredient: (1 result)